These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

137 related items for PubMed ID: 10725976

  • 1. Aberrations of the tissue factor pathway in patients positive for lupus anticoagulant.
    Wakita Y, Wada H, Nakase T, Nakasaki T, Shimura M, Hiyoyama K, Mori Y, Gabazza EC, Nishikawa M, Deguchi K, Shiku H.
    Clin Appl Thromb Hemost; 1999 Jan; 5(1):10-5. PubMed ID: 10725976
    [Abstract] [Full Text] [Related]

  • 2. Hemostatic abnormalities in patients with thrombotic complications on maintenance hemodialysis.
    Inoue A, Wada H, Takagi M, Yamamuro M, Mukai K, Nakasaki T, Shimura M, Hiyoyama K, Deguchi H, Gabazza EC, Mori Y, Nishikawa M, Deguchi K, Shiku H.
    Clin Appl Thromb Hemost; 2000 Apr; 6(2):100-3. PubMed ID: 10775031
    [Abstract] [Full Text] [Related]

  • 3. Impaired control of the tissue factor pathway of blood coagulation in systemic lupus erythematosus.
    Adams MJ, Palatinus AA, Harvey AM, Khalafallah AA.
    Lupus; 2011 Dec; 20(14):1474-83. PubMed ID: 21993387
    [Abstract] [Full Text] [Related]

  • 4. Changes of plasma tissue factor and tissue factor pathway inhibitor antigen levels and induction of tissue factor expression on the monocytes in coronary artery disease.
    Kim HK, Song KS, Park YS, Yun YS, Shim WH.
    Cardiology; 2000 Dec; 93(1-2):31-6. PubMed ID: 10894904
    [Abstract] [Full Text] [Related]

  • 5. Changes in the concentration and distribution of tissue factor pathway inhibitor in Behçet's disease and systemic lupus erythematosus: effect on the prethrombotic state.
    Ertenli I, Kiraz S, Celik IC, Haznedaroglu C, Erman M, Calgüneri M, Kirazli S.
    Ann Rheum Dis; 2001 Dec; 60(12):1149-51. PubMed ID: 11709459
    [Abstract] [Full Text] [Related]

  • 6. Poor outcome in disseminated intravascular coagulation or thrombotic thrombocytopenic purpura patients with severe vascular endothelial cell injuries.
    Wada H, Mori Y, Shimura M, Hiyoyama K, Ioka M, Nakasaki T, Nishikawa M, Nakano M, Kumeda K, Kaneko T, Nakamura S, Shiku H.
    Am J Hematol; 1998 Jul; 58(3):189-94. PubMed ID: 9662269
    [Abstract] [Full Text] [Related]

  • 7. Plasma tissue factor and tissue factor pathway inhibitor levels in patients with disseminated intravascular coagulation.
    Shimura M, Wada H, Wakita Y, Nakase T, Hiyoyama K, Nagaya S, Mori Y, Shiku H.
    Am J Hematol; 1997 Aug; 55(4):169-74. PubMed ID: 9257875
    [Abstract] [Full Text] [Related]

  • 8. Plasma tissue factor and tissue factor pathway inhibitor levels in patients with disseminated intravascular coagulation.
    Shimura M, Wada H, Wakita Y, Nakase T, Hiyoyama K, Nagaya S, Mori Y, Shiku H.
    Am J Hematol; 1996 Jul; 52(3):165-70. PubMed ID: 8756081
    [Abstract] [Full Text] [Related]

  • 9. [Analysis of behaviors of plasma tissue factor and tissue factor pathway inhibitor in patients with various diseases].
    Saito M, Morishita E, Asakura H, Jokaji H, Uotani C, Kumabashiri I, Yamazaki M, Aoshima K, Matsuda T.
    Rinsho Ketsueki; 1996 Sep; 37(9):794-8. PubMed ID: 8914465
    [Abstract] [Full Text] [Related]

  • 10. Increased tissue factor pathway inhibitor in patients with acute myocardial infarction.
    Kamikura Y, Wada H, Yamada A, Shimura M, Hiyoyama K, Shiku H, Tanigawa M, Nishikawa H, Yamada N, Isaka N, Nakano T, Kumeda K, Kato H.
    Am J Hematol; 1997 Aug; 55(4):183-7. PubMed ID: 9257877
    [Abstract] [Full Text] [Related]

  • 11. Plasma tissue factor and tissue factor pathway inhibitor in patients with primary glomerulonephritis.
    Lizakowski S, Zdrojewski Z, Jagodzinski P, Rutkowski B.
    Scand J Urol Nephrol; 2007 Aug; 41(3):237-42. PubMed ID: 17469034
    [Abstract] [Full Text] [Related]

  • 12. Tissue factor and tissue factor pathway inhibitor in nasal mucosa and nasal secretions of chronic rhinosinusitis with nasal polyp.
    Shimizu S, Ogawa T, Takezawa K, Tojima I, Kouzaki H, Shimizu T.
    Am J Rhinol Allergy; 2015 Aug; 29(4):235-42. PubMed ID: 26163243
    [Abstract] [Full Text] [Related]

  • 13. Evaluating systemic lupus erythematosus disease activity using molecular markers of hemostasis.
    Inoh M, Tokuda M, Kiuchi H, Kurata N, Takahara J.
    Arthritis Rheum; 1996 Feb; 39(2):287-91. PubMed ID: 8849381
    [Abstract] [Full Text] [Related]

  • 14. Changes of plasma hemostatic markers during percutaneous transluminal coronary angioplasty in patients with chronic coronary artery disease.
    Saito Y, Wada H, Yamamuro M, Inoue A, Shimura M, Hiyoyama K, Gabazza EC, Isaka N, Shiku H, Takeya H, Suzuki K, Kumeda K, Kato H, Nakano T.
    Am J Hematol; 1999 Aug; 61(4):238-42. PubMed ID: 10440909
    [Abstract] [Full Text] [Related]

  • 15. Relevance of tissue factor and tissue factor pathway inhibitor for hypercoagulable state in the lungs of patients with idiopathic pulmonary fibrosis.
    Fujii M, Hayakawa H, Urano T, Sato A, Chida K, Nakamura H, Takada A.
    Thromb Res; 2000 Jul 15; 99(2):111-7. PubMed ID: 10946084
    [Abstract] [Full Text] [Related]

  • 16. Effect of porcine endothelial tissue factor pathway inhibitor on human coagulation factors.
    Kopp CW, Siegel JB, Hancock WW, Anrather J, Winkler H, Geczy CL, Kaczmarek E, Bach FH, Robson SC.
    Transplantation; 1997 Mar 15; 63(5):749-58. PubMed ID: 9075849
    [Abstract] [Full Text] [Related]

  • 17. Increased activated protein C: protein C inhibitor complex and decreased protein C inhibitor levels in patients with chronic renal failure on maintenance hemodialysis.
    Takagi M, Wada H, Mukai K, Minamikawa K, Wakita Y, Deguchi K, Junji N, Hayashi T, Suzuki K, Shiku H.
    Clin Appl Thromb Hemost; 1999 Apr 15; 5(2):113-6. PubMed ID: 10725991
    [Abstract] [Full Text] [Related]

  • 18. Elevated tissue factor and tissue factor pathway inhibitor circulating levels in ischaemic heart disease patients.
    Falciani M, Gori AM, Fedi S, Chiarugi L, Simonetti I, Dabizzi RP, Prisco D, Pepe G, Abbate R, Gensini GF, Neri Serneri GG.
    Thromb Haemost; 1998 Mar 15; 79(3):495-9. PubMed ID: 9531029
    [Abstract] [Full Text] [Related]

  • 19. Coexpression of tissue factor and tissue factor pathway inhibitor by human monocytes purified by leukapheresis and elutriation. Response of nonadherent cells to lipopolysaccharide.
    Nguyên P, Broussas M, Cornillet-Lefèbvre P, Potron G.
    Transfusion; 1999 Sep 15; 39(9):975-82. PubMed ID: 10533824
    [Abstract] [Full Text] [Related]

  • 20. Coagulation activity and thrombotic risk following high-volume endurance exercise in recreationally active cyclists.
    Collins BEG, Kingsley M, Gordon BA, Zadow EK, Wundersitz DWT.
    J Appl Physiol (1985); 2024 May 01; 136(5):1284-1290. PubMed ID: 38572538
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.